Rapid ganciclovir susceptibility assay using flow cytometry for human cytomegalovirus clinical isolates

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 9, 1998, Pages 2326-2331

  McSharry, James J ^a   Lurain, Nell S ^b   Drusano, George L ^a   Landay, Alan L ^b   Notka, Mostafa ^c   O'Gorman, Maurice R G ^d   Weinberg, Adriana ^e   Shapiro, Howard M ^h   Reichelderfer, Patricia S ^f   Crumpacker, Clyde S ^g  

^a ALBANY MEDICAL COLLEGE   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^d CHILDREN'S MEMORIAL HOSPITAL   (United States)

^e UNIVERSITY OF COLORADO HOSPITAL   (United States)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

^g BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^h Albany Medical College ^*

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; IMMEDIATE EARLY PROTEIN;

ANTIBIOTIC SENSITIVITY; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ANTIVIRAL ACTIVITY; ARTICLE; CHRONOLOGY; EMBRYO; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; IMMUNOASSAY; LUNG FIBROBLAST; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; REPRODUCIBILITY; SKIN FIBROBLAST; VIRUS ISOLATION;

EID: 0031664165     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.9.2326     Document Type: Article

References (34)

1. AIDS Clinical Trials Group. Antiviral susceptibility assay for CMV: plaque eduction method. ACTG Viral Co-Pathogens Working Group consensus procedure. AIDS Clinical Trials Group.
2. Arts, E., and M. A. Wainberg. 1996. Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription. Antimicrob. Agents Chemother. 40:527-540.
3. Chatis, P., and C. S. Crumpacker. 1992. Resistance of herpesviruses to antiviral drugs. Antimicrob. Agents Chemother. 36:1589-1595.
4. Chou, S., A. Erice, M. C. Jordan, G. M. Vercellotti, K. R. Michels, C. L. Talarico, S. C. Stanat, and K. K. Biron. 1995. Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance. J. Infect. Dis. 171:576-583.
5. Chou, S., S. Geuntzel, K. R. Michels, R. C. Miner, and W. L. Drew. 1995. Frequency of UL97 phosphotransferase mutations related to ganciclovir resistance in clinical cytomegalovirus isolates. J. Infect. Dis. 172:239-254.
6. Chou, S., G. Marousek, S. Guentzel, S. E. Follansbee, M. E. Poscher, J. P. Lalezari, R. C. Miner, and W. L. Drew. 1997. Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. J. Infect. Dis. 176:786-789.
7. Crumpacker, C. S. 1989. Molecular targets of antiviral therapy. N. Engl. J. Med. 321:163-172.
8. Crumpacker, C. S. 1996. Ganciclovir. N. Engl. J. Med. 335:721-729.
9. Crumpacker, C. S. 1996. Drug resistance in cytomegalovirus: current knowledge and implications for patient management. J. Acquired Immune Defic. Syndr. 12(Suppl. 1):S18.
10. D'Aquila, R. T., V. A. Johnson, S. L. Wells, A. J. Japour, D. R. Kurtizkes, V. DeGruttola, P. S. Reichelderfer, R. W. Combs, C. S. Crumpacker, J. O. Kahn and D. D. Richman for the AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group. 1995. Zidovudine resistance and human immunodeficiency virus type 1 disease progression during antiretroviral therapy. Ann. Intern. Med. 122:401-408.
11. D'Argenio, D. Z., and A. Schumitzky. 1997. ADAPT II user's guide: pharmacokinetic/pharmacodynamic systems analysis software. Biomedical Simulations Resources, Los Angeles, Calif.
12. De Clercq, E. 1997. In search of a selective antiviral chemotherapy. Clin. Microbiol. Rev. 10:674-693.
13. Drew, W. L., R. C. Minor, D. F. Busch, S. E. Follansbee, J. Gullett, S. G. Mehalko, S. M. Gordon, W. F. Owen, Jr., T. R. Mathews, W. C. Buhles, and B. DeArmond. 1991. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J. Infect. Dis. 163:716-719.
14. Elmendorf, S., J. J. McSharry, J. Laffin, D. Fogleman, and J. M. Lehman. 1988. Detection of an early cytomegalovirus antigen with two color quantitative flow cytometry. Cytometry 9:254-260.
15. Erice, A., C. Gil-Roda, J.-L. Perez, H. H. Balfour, Jr., K. J. Sannerud, M. N. Hanson, G. Boivin, and S. Chou. 1997. Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. J. Infect. Dis. 175:1087-1092.
16. Erlich, K. S., J. Mills, P. Chatis, G. J. Mertz, D. Bush, S. Follansbee, R. M. Grant, and C. S. Crumpacker. 1989. Acyclovir-resistant HSV infections in patients with AIDS. N. Engl. J. Med. 320:293-296.
17. Gerna, F., A. Sarasini, E. Percivalle, M. Zavattoni, F. Baldanti, and M. G. Revello. 1995. Rapid screening for resistance to ganciclovir and foscarent resistance of primary isolates of human cytomegalovirus from culture positive blood samples. J. Clin. Microbiol. 33:738-741.
18. Hirsch, M. S., J. C. Kaplan, and R. T. D'Aquila. 1996. Antiviral agents, p. 431-466. In B. N. Fields, D. M. Knipe, and P. Howley (ed.), Fields virology. Lippincott-Raven Press, Philadelphia, Pa.
19. Japour, A. J., D. L. Mayer, V. A. Johnson, D. R. Kuritzkes, L. A. Beckett, J.-M. Arduino, J. Lane, R. J. Black, P. S. Reichelderfer, R. T. D'Aquila, C. S. Crumpacker, the RV-43 Study Group, and the AIDS Clinical Trials Group Virology Committee Resistance Working Group. 1993. Standardized peripheral blood monomuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother. 37:1095-1101.
20. Japour, A. J., S. L. Wells, R. T. D'Aquila, V. A. Johnson, D. D. Richman, R. W. Coombs, P. S. Reichelderfer, J. O. Kahn, V. DeGruttola, C. S. Crumpacker, and D. T. Kuritzkes for the AIDS Clinical Trials Group 116B/117 Study Team and the Virology Committee Resistance Working Group. 1995. Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients following long-term zidovudine treatment. J. Infect. Dis. 171:1172-1179.
21. Jokela, J., A. Erice, S. Stanat, W. L. Drew, S. Spector, A. Weinberg, B. Gilliam, B. Yen-Lieberman, J. Manischewitz, R. Pollard, M. Landry, S. Chou, K. Biron, P. S. Reichelderfer, W. Britt, and C. Crumpacker. 1995. A standardized plaque reduction assay for CMV antiviral susceptibility, abstr. 283. In Abstracts of the 2nd National Conference on Human Retroviruses.
22. Lipson, S. M., M. Soni, F. X. Biondo, D. H. Shepp, M. H. Kaplan, and T. Sun. 1997. Antiviral susceptibility testing-flow cytometric analysis (AST-FCA) for the detection of cytomegalovirus drug resistance. Diagn. Microbiol. Infect. Dis. 28:123-129.
23. Lurain, N. S., H. C. Ammons, K. S. Kapell, V. V. Yeldandi, E. R. Garrity, and J. P. O'Keefe. 1996. Molecular analysis of human cytomegalovirus strains from two lung transplant recipients with the same donor. Transplantation 62: 497-502
24. Lurain, N. S., K. D. Thompson, E. W. Holmes, and G. S. Read. 1992. Point mutations in the DNA polymerase gene of human cytomegalovirus that result in resistance to antiviral agents. J. Virol. 66:7146-7152.
25. McSharry, J. J. 1994. Uses of flow cytometry in virology. Clin. Microbiol. Rev. 7:576-604.
26. McSharry, J. J. 1995. Flow cytometry based antiviral resistance assays. Clin. Immunol. Newsl. 15:113-119.
27. McSharry, J. J., N. S. Lurain, G. L. Drusano, A. Landay, J. Manischewitz, M. Nokta, M. O'Gorman, H. M. Shapiro, A. Weinberg, P. S. Reichelderfer, and C. S. Crumpacker. 1998. Flow cytometric determination of ganciclovir susceptibility of human cytomegalovirus clinical isolates. J. Clin. Microbiol. 36:958-964.
28. Mocarski, E. S., Jr. 1996. Cytomegaloviruses and their replication, p. 2447-2492. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology. Lippencott-Raven Publishers, Philadelphia, Pa.
29. Pavic, I., A. Hartmann, A. Zimmermann, D. Michel, W. Hampl, I. Schleyer, and T. Mertens. 1997. Flow cytometric analysis of herpes simplex virus type 1 susceptibility to acyclovir, ganciclovir, and foscarnet. Antimicrob. Agents Chemother. 41:2686-2692.
30. Pepin, J.-M., F. Simon, A. Dussault, G. Collin, M.-C. Dazza, and F. Brun-Vezinet. 1992. Rapid detection of human cytomegalovirus susceptibility to ganciclovir directly from clinical specimen primocultures. J. Clin. Microbiol. 30:2917-2920.
31. Rosenthal, K. S., C. N. Hodnichak, and J. L. Summers. 1987. Flow cytometric evaluation of anti-herpes drugs. Cytometry 8:392-395.
32. Schols, D., R. Snoeck, J. Neyts, and E. DeClercq. 1989. Detection of immediate early, early and late antigens of human cytomegalovirus by flow cytometry. J. Virol. 26:247-254.
33. Stanat, S. C., J. E. Reardon, A. Erice, M. C. Jordan, W. L. Drew, and K. K. Biron. 1991. Ganciclovir-resistant cytomegalovirus clinical isolates: mode of resistance to ganciclovir. Antimicrob. Agents Chemother. 35:2191-2197.
34. Wentworth, B. B., and L. French. 1970. Plaque assay of cytomegalovirus strains of human origin. Proc. Soc. Exp. Biol. Med. 135:253-258.